TargetBeta
MTOR
mechanistic target of rapamycin kinase · also mTOR, RAFT1, RAPT1, FLJ44809 · MTOR complex 1
4 programs in company-led studies act on MTOR, from 3 companies: 2 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Sirolimus | Pfizer | phase 4 | 6615 running | – | a judged reading |
| PI3K/mTOR Kinase Inhibitor WXFL10030390rule | Shanghai Jiatan Pharmatech | phase 3 | 64 running | – | NCIt |
| gedatolisibrule | Pfizer | phase 3 | 93 running | PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3R2, PIK3R3, PIK3R5 | NCIt |
| sapanisertibrule | Takeda | phase 2 | 142 running | – | ChEMBL |
Conditions their studies are in
- Breast Neoplasms, 3 programs
- Endometrial Neoplasms, 2 programs
- Carcinoma, Non-Small-Cell Lung, 1 program
- Clear-cell metastatic renal cell carcinoma, 1 program
- Colorectal Neoplasms, 1 program
- Diabetic Neuropathies, 1 program
- Kidney Failure, Chronic, 1 program
- Neoplasms, 1 program
- Prostatic Neoplasms, Castration-Resistant, 1 program
- Renal Insufficiency, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Feb 2027Sirolimus · Pfizer · phase 4 · NCT04411654
- Jan 2028gedatolisib · Pfizer · phase 3 · NCT06190899
- Sep 2028sapanisertib · Takeda · phase 2 · NCT06463028
- Sep 30, 2029PI3K/mTOR Kinase Inhibitor WXFL10030390 · Shanghai Jiatan Pharmatech · phase 3 · NCT07392060
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.